Professional or Occupational Group

Arch Biopartners Appoints Dr. Patrick Vink as Chairman of the Board

7 days ago talkbio0Tagged Arch Biopartners, board of directors, Chairperson, Claude Allary, kidney therapeutics, Patrick Vink

Arch Biopartners; Patrick Vink; Chairman; Board of Directors; Claude Allary; kidney therapeutics

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

2025 FDA staff cuts and their impact on new drug review timelines

2 weeks ago talkbio0Tagged 2025, CHARGE Syndrome, Drug Approval, drug review, HHS, layoffs, PDUFA, Programs - Publication Format, regulatory timelines, RFK gene, Staff, TimeLine Fluoride Releasing Resin, United States Food and Drug Administration, user fee, Workforce

FDA layoffs 2025; drug review timelines; user fee programs; HHS staff cuts; RFK Jr. layoffs; PDUFA; regulatory timelines; drug approvals; FDA workforce reductions

Lunit SCOPE AI Achieves High Concordance in HER2 Assessment for Biliary Tract Cancer

3 weeks ago talkbio0Tagged Agreement, Biliary Tract Cancer, erbB-2 Receptor, Lunit SCOPE, Medical pathologist, Pathology

Lunit SCOPE; HER2; biliary tract cancer; AI pathology; concordance; pathologists

Pfizer, Geron Downsize to Streamline Costs

1 month ago talkbio0Tagged commercial strategy, cost-cutting, Geron, Pfizer, Rytelo, Staff, Switzerland

Pfizer layoffs Switzerland; Geron layoffs one-third staff; cost-cutting; restructuring plan; Rytelo commercial strategy; Pfizer cost realignment; biopharma layoffs 2025

Rakovina Therapeutics Announces Q3 2025 Financial Results and Corporate Update

2 months ago talkbio0Tagged AI-powered, ATR Inhibitor, Clinical Nurse Specialists, Conferences, corporate milestones, development expenses, Ditiocarb, Drug Discovery, Eligibility Determination, financial results, Investments, NanoPalm joint-venture, net loss, Penetration, Q3, Rakovina, research

Rakovina Therapeutics; Q3 2025; financial results; net loss; research and development expenses; AI-powered drug discovery; ATR inhibitor; CNS penetration; corporate milestones; NanoPalm joint-venture; investment conference; DTC eligibility

White House Requests Resignation of Top FDA Aide, Prompting Tensions with Commissioner Makary

2 months ago talkbio0Tagged CHARGE Syndrome, controversy, internal tensions, management technique, Marty Makary, resignation, Sanjula Jain-Nagpal, United States Food and Drug Administration, White House, Workforce - population group

FDA; White House; Marty Makary; Sanjula Jain-Nagpal; resignation; HHS; staffing controversy; Robert F. Kennedy Jr.; management style; internal tensions

Edgewise Therapeutics Appoints Christopher Martin to its Board of Directors

2 months ago talkbio0Tagged Acquisition, Becker Muscular Dystrophy, board of directors, cardiovascular asset, Christopher Martin, commercial, Edgewise Therapeutics, executives, Leadership, Merck, Verona Pharma

Edgewise Therapeutics; Christopher Martin; Board of Directors; biotech executive; commercial leadership; Becker muscular dystrophy; cardiovascular asset; Verona Pharma; Merck acquisition